Trastuzumab induced cardiotoxicity in patients with HER2+ breast cancer

• Autores: Elena Capilla Santamaría, B. Benítez García, José Antonio Romero Garrido, P. Zamora Auñon, Gema Casado Abad
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 15, Nº. 4, 2013, págs. 261-267
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To assess the incidence of trastuzumab induced cardiotoxicity in clinical practice. Method: A retrospective study was conducted on HER2+ breast cancer patients who started treatment with trastuzumab in 2008 and 2009, and were monitored for one year. Results: 67 patients were included. The cardiotoxicity incidence was 46.3% with a mean time of onset from 5.5±3.3 months. The most commonly criterion was the decline in LVEF (Left Ventricular Ejection Fraction) >10 points from baseline value (28.4%). 45.1% of the cases were symptomatic cardiotoxicity. A baseline LVEF of >67% was associated with cardiotoxicity (p<0.05). Conclusions: The incidence of cardiotoxicity in clinical practice was higher than that obtained in different clinical trials. It is necessary to reach consensus between professionals to ensure the drug's safety without limiting benefit for the patient